These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37982959)

  • 61. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
    Diel IJ; Kaufmann M; Costa SD; Holle R; von Minckwitz G; Solomayer EF; Kaul S; Bastert G
    J Natl Cancer Inst; 1996 Nov; 88(22):1652-8. PubMed ID: 8931609
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Surgeon specialization and use of sentinel lymph node biopsy for breast cancer.
    Yen TW; Laud PW; Sparapani RA; Nattinger AB
    JAMA Surg; 2014 Feb; 149(2):185-92. PubMed ID: 24369337
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
    Sávolt Á; Cserni G; Lázár G; Maráz R; Kelemen P; Kovács E; Győrffy B; Udvarhelyi N; Vörös A; Ormándi K; Mátrai Z
    Eur J Surg Oncol; 2019 Oct; 45(10):1835-1838. PubMed ID: 31126680
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database.
    Kawachi I; Okamoto S; Sakamoto M; Ohta H; Nakamura Y; Iwasaki K; Yoshida M; Hiroi S; Ogino M
    BMC Neurol; 2019 Dec; 19(1):324. PubMed ID: 31842786
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
    Fujita S; Akasu T; Mizusawa J; Saito N; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Shiozawa M; Yamaguchi T; Moriya Y;
    Lancet Oncol; 2012 Jun; 13(6):616-21. PubMed ID: 22591948
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Breast Cancer Subtype is Associated With Axillary Lymph Node Metastasis: A Retrospective Cohort Study.
    He ZY; Wu SG; Yang Q; Sun JY; Li FY; Lin Q; Lin HX
    Medicine (Baltimore); 2015 Dec; 94(48):e2213. PubMed ID: 26632910
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017-2019.
    Seweryn M; Banas T; Augustynska J; Lorenc O; Kopel J; Pluta E; Skora T
    Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554267
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Temporal Trend in an Initial Treatment, Survival, and Medical Costs Among Patients With Lung Cancer Between 2013 and 2018 in Kyoto City, Japan.
    Shimamoto T; Tateyama Y; Kobayashi D; Yamamoto K; Takahashi Y; Ueshima H; Sasaki K; Nakayama T; Iwami T
    Value Health Reg Issues; 2022 Sep; 31():163-168. PubMed ID: 35777173
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Breast Cancer Population Screening Program Results in Early Detection and Reduced Treatment and Health Care Costs for Medicaid.
    Homan SG; Yun S; Bouras A; Schmaltz C; Gwanfogbe P; Lucht J
    J Public Health Manag Pract; 2021; 27(1):70-79. PubMed ID: 31592983
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
    Shiroiwa T; Fukuda T; Shimozuma K; Mouri M; Hagiwara Y; Kawahara T; Ohsumi S; Hozumi Y; Sagara Y; Ohashi Y; Mukai H
    BMC Cancer; 2017 Nov; 17(1):773. PubMed ID: 29149882
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Prospects for standardization of surgical treatment for breast cancer].
    Tajima T
    Nihon Geka Gakkai Zasshi; 2003 May; 104(5):427-31. PubMed ID: 12774528
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt.
    Dominici LS; Sineshaw HM; Jemal A; Lin CC; King TA; Freedman RA
    Breast Cancer Res Treat; 2018 Jan; 167(2):555-566. PubMed ID: 28990127
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Determining breast cancer axillary surgery within the surveillance epidemiology and end results-Medicare database.
    Schmocker RK; Caretta-Weyer H; Weiss JM; Ronk K; Havlena J; Loconte NK; Decker M; Smith MA; Greenberg CC; Neuman HB
    J Surg Oncol; 2014 Jun; 109(8):756-9. PubMed ID: 24643795
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach.
    Khan SA; Hernandez-Villafuerte K; Hernandez D; Schlander M
    Front Public Health; 2022; 10():946544. PubMed ID: 36684975
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation.
    Cooper KL; Meng Y; Harnan S; Ward SE; Fitzgerald P; Papaioannou D; Wyld L; Ingram C; Wilkinson ID; Lorenz E
    Health Technol Assess; 2011 Jan; 15(4):iii-iv, 1-134. PubMed ID: 21276372
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Does ultrasound evaluation of the axilla increase the rate of axillary lymph node dissection in early stage clinically node negative breast cancer patients?
    Vasigh M; Meshkati Yazd SM; Karoobi M; Hajebi R; Yazdankhah Kenari A
    BMC Surg; 2022 Mar; 22(1):80. PubMed ID: 35241059
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of axillary lymph node dissection on breast cancer outcome in clinically node negative patients: a systematic review and meta-analysis.
    Sanghani M; Balk EM; Cady B
    Cancer; 2009 Apr; 115(8):1613-20. PubMed ID: 19199349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.